Adenocarcinoma

BARCELONA — One-third of health care professionals reported a lack of knowledge about evidence-based guidelines for molecular testing of lung cancer, according to survey results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Patients with Barrett’s Esophagus with indefinite for dysplasia are at similar risk for malignant progression and should be screened like patients with low-grade dysplasia, according to results of a meta-analysis published in Gastrointestinal Endoscopy. “Currently, there are no reliable estimates for progression risk to [high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC)] in patients with [Barrett’s esophagus with indefinite for dysplasia (BE-IND)],” Prasad G. Iyer, MD, MSc, from the division of gastroenterology and hepatology at Mayo Clinic in Rochester, Minnesota, and colleagues wrote. “Hence, management strategies for BE-IND are unclear and endoscopy is not routinely recommended.”